Overview
The marketing authorisation for Humenza has been withdrawn at the request of the marketing authorisation holder.
Humenza : EPAR - Summary for the public
English (EN)
(284.6 KB - PDF)View
български (BG)
(381.06 KB - PDF)
español (ES)
(347.22 KB - PDF)
čeština (CS)
(408.63 KB - PDF)
dansk (DA)
(349.2 KB - PDF)
Deutsch (DE)
(349.27 KB - PDF)
eesti keel (ET)
(345.61 KB - PDF)
ελληνικά (EL)
(451.37 KB - PDF)
français (FR)
(350.82 KB - PDF)
italiano (IT)
(349.94 KB - PDF)
latviešu valoda (LV)
(413.32 KB - PDF)
lietuvių kalba (LT)
(378.27 KB - PDF)
magyar (HU)
(401.83 KB - PDF)
Malti (MT)
(348.95 KB - PDF)
Nederlands (NL)
(346.99 KB - PDF)
polski (PL)
(409.39 KB - PDF)
português (PT)
(347.01 KB - PDF)
română (RO)
(378.01 KB - PDF)
slovenčina (SK)
(406.2 KB - PDF)
slovenščina (SL)
(398.8 KB - PDF)
Suomi (FI)
(348.79 KB - PDF)
svenska (SV)
(345.83 KB - PDF)
Product information
Humenza : EPAR - Product Information
English (EN)
(589.67 KB - PDF)View
български (BG)
(1.45 MB - PDF)
español (ES)
(551.35 KB - PDF)
čeština (CS)
(1.23 MB - PDF)
dansk (DA)
(655.75 KB - PDF)
Deutsch (DE)
(595.99 KB - PDF)
eesti keel (ET)
(572.19 KB - PDF)
ελληνικά (EL)
(1.42 MB - PDF)
français (FR)
(582.58 KB - PDF)
italiano (IT)
(651.9 KB - PDF)
latviešu valoda (LV)
(1.07 MB - PDF)
lietuvių kalba (LT)
(732.84 KB - PDF)
magyar (HU)
(1.01 MB - PDF)
Malti (MT)
(1.03 MB - PDF)
Nederlands (NL)
(589.7 KB - PDF)
polski (PL)
(1.12 MB - PDF)
português (PT)
(581.22 KB - PDF)
română (RO)
(693.71 KB - PDF)
slovenčina (SK)
(1.02 MB - PDF)
slovenščina (SL)
(997.09 KB - PDF)
Suomi (FI)
(579.58 KB - PDF)
svenska (SV)
(600.72 KB - PDF)
Latest procedure affecting product information: -
14/06/2011
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Humenza : EPAR - All Authorised presentations
English (EN)
(239.26 KB - PDF)View
български (BG)
(376.55 KB - PDF)
español (ES)
(259.23 KB - PDF)
čeština (CS)
(281.68 KB - PDF)
dansk (DA)
(259.63 KB - PDF)
Deutsch (DE)
(260.52 KB - PDF)
eesti keel (ET)
(259.14 KB - PDF)
ελληνικά (EL)
(295.04 KB - PDF)
français (FR)
(259.21 KB - PDF)
italiano (IT)
(257.88 KB - PDF)
latviešu valoda (LV)
(283.41 KB - PDF)
lietuvių kalba (LT)
(273.45 KB - PDF)
magyar (HU)
(282.62 KB - PDF)
Malti (MT)
(283.55 KB - PDF)
Nederlands (NL)
(259.53 KB - PDF)
polski (PL)
(283.89 KB - PDF)
português (PT)
(259.46 KB - PDF)
română (RO)
(270.81 KB - PDF)
slovenčina (SK)
(281.75 KB - PDF)
slovenščina (SL)
(263.79 KB - PDF)
Suomi (FI)
(258.94 KB - PDF)
svenska (SV)
(259.94 KB - PDF)
Product details
- Name of medicine
- Humenza
- Active substance
- split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs.
- International non-proprietary name (INN) or common name
- pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
- Therapeutic area (MeSH)
- Influenza, Human
- Immunization
- Disease Outbreaks
- Anatomical therapeutic chemical (ATC) code
- J07BB02
Pharmacotherapeutic group
VaccinesTherapeutic indication
Prophylaxis of influenza in an officially declared pandemic situation.
Pandemic influenza vaccine should be used in accordance with Official Guidance.
Assessment history
This page was last updated on